JPH0348624A - Therapy of asthma by iron component elimination - Google Patents
Therapy of asthma by iron component eliminationInfo
- Publication number
- JPH0348624A JPH0348624A JP18343789A JP18343789A JPH0348624A JP H0348624 A JPH0348624 A JP H0348624A JP 18343789 A JP18343789 A JP 18343789A JP 18343789 A JP18343789 A JP 18343789A JP H0348624 A JPH0348624 A JP H0348624A
- Authority
- JP
- Japan
- Prior art keywords
- asthma
- iron component
- iron
- therapy
- zinc sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 208000006673 asthma Diseases 0.000 title claims abstract description 18
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 15
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 230000008030 elimination Effects 0.000 title 1
- 238000003379 elimination reaction Methods 0.000 title 1
- 210000000621 bronchi Anatomy 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 210000003403 autonomic nervous system Anatomy 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract description 6
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 abstract description 5
- 229960001763 zinc sulfate Drugs 0.000 abstract description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 abstract description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- IPCXNCATNBAPKW-UHFFFAOYSA-N zinc;hydrate Chemical compound O.[Zn] IPCXNCATNBAPKW-UHFFFAOYSA-N 0.000 abstract 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】 （イ）産業上の利用分野 この発明はぜん息の治療法に関する。[Detailed description of the invention] (b) Industrial application field This invention relates to a method for treating asthma.
（ロ）従来の技術
ぜん息そのものは、気管支の冷え込みによるものと考え
られ、それに対して温熱療法で気管支を温める方法が行
われていると思うが祥細ば゛我々には明らかではない。(b) Conventional technology Asthma itself is thought to be caused by the coldness of the bronchial tubes, and in response to this, heat therapy is thought to be used to warm the bronchial tubes, but the exact details are not clear to us.
要は、気管支が温くなれば発作は起こらないのだから、
おそら（気管支を温めることに腐心しているものと考え
られる。勿論それによってせきは一時的に止まるのだが
、原因である鉄分は、それによっては立ち去ってはくれ
ない。The point is, if the bronchi become warm, attacks will not occur.
He is probably trying to warm up his bronchial tubes. Of course, this will temporarily stop the cough, but the iron that is causing it will not go away.
寧ろ、気管支を温めることは、熱によって集合した鉄分
に、何時までも、そこにいすわる口実を与えるようなも
のであり、悪化する懸念さえある。On the contrary, warming the bronchial tubes is like giving the iron collected by the heat an excuse to sit there indefinitely, and there are concerns that it may even worsen.
（ハ）発明を解決しようとする課題
光づ、ぜん息の主因である鉄分の気管支の中の状態を知
る必要がある。(c) Problems to be Solved by the Invention First, it is necessary to know the state of iron in the bronchi, which is the main cause of asthma.
気管支が何かの原因で熱（なり、それを冷却する為に、
酸化鉄が入り込んで来る。その酸化鉄はより効果を高め
る為に、酸化鉄の酸を除外する。そうすることによって
、気管支は、更に冷だ（なり、平熱となるが、酸化鉄は
その間に変化し、当初の任務が終わっても元には戻らな
くなる。そればかりでなく、酸化鉄にも還らなくなる。The bronchi become feverish for some reason, and in order to cool it down,
Iron oxide comes in. The iron oxide excludes the acid of iron oxide in order to increase its effectiveness. By doing so, the bronchi become even colder (and become normal), but the iron oxide changes during that time and does not return to its original state even after its original mission is completed. It disappears.
従って、有害な鉄を如何にして処理するかが、ぜん息の
治療の課題である。Therefore, how to dispose of harmful iron is an issue in the treatment of asthma.
（ニ）発明を解決する為の手段
分裂した鉄は、気管支に残留しこびりついて離れないか
ら、ぜん息となるのだから、それを引き離すには、元の
酸化鉄に戻さなければならない。だが、通常の酸では、
鉄と融合させようとしても、鉄と酸が等価にならなけれ
ば、酸化鉄とはならない。(d) Means for solving the invention Splintered iron remains in the bronchial tubes and cannot be removed, causing asthma, so in order to remove it, it must be returned to its original form of iron oxide. However, with normal acids,
Even if you try to fuse it with iron, it will not become iron oxide unless the iron and acid become equivalent.
その為には、鉄と酸の仲介して（れる仲人が必要になっ
て来る。それが今回の出願の要である炭酸ナトＩＪウム
が主役である。To do this, a mediator is needed to mediate between iron and acid. Sodium carbonate, which is the key to this application, plays a leading role.
炭酸す） ＩＪウム１０に対し、硫酸亜鉛１以下の割合
で、それに水を加えて濃厚な水溶液を作り、患部に塗布
する。その場合塗布薬全体が過酸化にならないよう注意
しなければならない。過酸化となると全熱効果がないば
かりか、逆効果となるから注意しなければならない。Add water to make a concentrated aqueous solution at a ratio of less than 1 part zinc sulfate to 10 parts IJum, and apply it to the affected area. In this case, care must be taken to ensure that the entire liniment does not become peroxidized. If it becomes peroxidized, not only will there be no total heating effect, but it will have the opposite effect, so care must be taken.
過酸化は、硫酸亜鉛の過剰によって起こるのだが、硫酸
亜鉛は鉄を排除する役目を持っているのだから必要な要
素であり、除くわけにはいかない。Peroxidation is caused by an excess of zinc sulfate, but since zinc sulfate has the role of eliminating iron, it is a necessary element and cannot be eliminated.
以上の方法で有害な鉄は無害となり、排除されるのだか
ら・、根本的な治癒となり、再発ということもなく、短
時日で治癒する完全なる治療法である。Since the above method makes harmful iron harmless and eliminates it, it is a complete treatment that provides a fundamental cure, does not cause recurrence, and cures in a short period of time.
（ホ）作 用
以上の方法で１日２回位、１回５時−間位の湿布で充分
である。長時間継続すると、患部が赤くなり、痛みが生
じるからである。塗布を中止すれば、２日位でその症状
はなくなる。(e) Effect Using the method described above, applying a compress about twice a day for about 5 hours at a time is sufficient. This is because if continued for a long time, the affected area will become red and painful. If you stop applying, the symptoms will disappear in about 2 days.
治療は、精々３日位で治療は完了する。外に副作用は絶
対になく、注意しなければならないことは、外にぜん息
の薬は併用しないことである。The treatment can be completed in about 3 days at most. There are absolutely no side effects, and one thing to be careful about is not to take other asthma medicines at the same time.
（へ）効 果
小児ぜん息などでも同等激痛もなく、１日にして小児の
せきが止まるのだから、喜んで施療を受ける。ぜん息の
苦しみも２〜３日で解除されるのだから効果は計り知れ
ないものと確信している。(f) Effect: Children with asthma or other conditions do not have the same severe pain and children's coughs stop within a day, so they are happy to receive the treatment. I am sure that the effects will be immeasurable, as the pain of asthma will be relieved in 2 to 3 days.
う＝−４面４−７U = -4 side 4-7
Claims (1)
経の誤りから、有害となることも多い。その見本のよう
なものがぜん息である。 ぜん息は、気管支の細胞というより、カルシウムの中に
喰い込んだ鉄分の為に起こるのだから、それを除去する
ことによって、完全に、しかも短時日に、治療すること
の出来る鉄分除去によるぜん息の治療法。[Claims] Iron is an important element for living things. However, errors in the autonomic nervous system can often be harmful. Asthma is a good example of this. Asthma is caused not by the cells of the bronchus but by the iron absorbed into the calcium, so by removing it, you can treat asthma completely and in a short period of time. .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18343789A JPH0348624A (en) | 1989-07-14 | 1989-07-14 | Therapy of asthma by iron component elimination |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18343789A JPH0348624A (en) | 1989-07-14 | 1989-07-14 | Therapy of asthma by iron component elimination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0348624A true JPH0348624A (en) | 1991-03-01 |
Family
ID=16135755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18343789A Pending JPH0348624A (en) | 1989-07-14 | 1989-07-14 | Therapy of asthma by iron component elimination |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0348624A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5498360A (en) * | 1993-06-30 | 1996-03-12 | Nomura Kohsan Co., Ltd. | Process for recycling used-up dry cells, and ferrite production process |
-
1989
- 1989-07-14 JP JP18343789A patent/JPH0348624A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5498360A (en) * | 1993-06-30 | 1996-03-12 | Nomura Kohsan Co., Ltd. | Process for recycling used-up dry cells, and ferrite production process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weil et al. | Treatment of insomnia in an eleven-year-old child through self-relaxation | |
| Exton et al. | Cold packs: Effective topical analgesia in the treatment of painful stings by Physalia and other jellyfish (for editorial comment, see page 610; see also pages 621, 626 and 708) | |
| DE3482754D1 (en) | MEDICINE AND MEDICINE POSSIBLE COMPOSITION FOR TREATING AND / OR PREVENTING SKIN DISEASES CAUSED BY INFLAMMATION. | |
| JP2004524327A5 (en) | ||
| DK95482A (en) | PROCEDURE FOR THE PREPARATION OF AROYLIMIDAZOLONS | |
| Cheetham et al. | Rabies with myocarditis: two cases in England | |
| de CAMARA et al. | Ultrastructural aspects of cooled thermal injury | |
| JPH0348624A (en) | Therapy of asthma by iron component elimination | |
| Harkins | The present status of the problem of thermal burns | |
| Sachs et al. | Paroxysmal complete auriculo-ventricular heart-block: A case report | |
| Braude et al. | Clonazepam: effective treatment for restless legs syndrome in uraemia. | |
| Orenchuk-Tomiuk et al. | The resolution model: A comprehensive treatment framework in sexual abuse | |
| US20050148658A1 (en) | Method for preventing and treating severe acute respiratory syndrome | |
| Winter | Carotid body resection in chronic obstructive pulmonary disease | |
| Kleiner | THE RELATIONSHIP OF INTERPERSONAL PROBLEMS TO THE DEVELOPMENT AND TREATMENT OF AGORAPHOBIA. | |
| Narlewad et al. | Ayurvedic management of Alopecia Areata-A Single Case Study | |
| DK338583A (en) | PROCEDURE AND MEDICINE FOR REDUCING TISSUE LESIONS IN AN ANIMAL | |
| Holve | Venomous spiders, snakes, and scorpions in the United States | |
| Eccles et al. | In vivo desensitization in the treatment of recurrent nightmares | |
| Anderson | Syphilis and AIDS. | |
| Gate | Lignocaine with Adrenaline | |
| Newman | Inactivated polyvalent influenza virus vaccine-a controlled study of its efficacy in the prevention of respiratory illness in industrial workers | |
| Ellis | Elastic Ankle-bands and Cramp | |
| Jaworski | Plantar Warts | |
| Irving | “Pethilorfan” in Domiciliary Obstetrics |